Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of intermediate lymphocytic lymphoma

Abstract

Methods of treating, preventing or managing mantle cell lymphomas are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention. further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention. are also disclosed.

What is claimed is: 
     
         1 . A method of treating mantic cell lymphoma in a human, which comprises administering to a human having mantle cell lymphoma from about 5 mg to about 50 mg of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2yl)-peridine-2,6-dione. 
     
     
         2 . The method of  claim 1 , wherein the mantle cell lymphoma is relapsed, refractory or resistant to conventional therapy. 
     
     
         3 . The method of  claim 2 , wherein the amount of 3-(4-amino-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2,6-dione administered is from about 5 mg to about 25 mg per day. 
     
     
         4 . The method of  claim 3 , wherein the amount of 3-(4-amino-oxo-1, 3-dihydro-isointiol-2-yl)-piperidine-2,6-dione administered is about 10, 15, 20 or 25 mg per day. 
     
     
         5 . The method of  claim 4 , wherein the amount of 3-(4-amino-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2,6-dione administered is about 25 mg per day. 
     
     
         6 . The method of  claim 3 , wherein 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione administered is enantiomerically pure. 
     
     
         7 . The method of  claim 6 , wherein 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione administered is S enantiomer. 
     
     
         8 . The method of  claim 6 , wherein 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione administered is R enantiomer. 
     
     
         9 . The method of  claim 3 , wherein 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione is administered orally. 
     
     
         10 . The method of  claim 9 , wherein 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione is administered in the form of a capsule or tablet. 
     
     
         11 . The method of  claim 3 , wherein 3-(4-amino-oxo-1,3-dihydro-isoindoI-2-yl)-piperidine-2, 6-dione is administered for 21 days followed by seven days rest in a 28 day cycle. 
     
     
         12 . The method of  claim 11 , wherein 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione is administered in an amount of about 25 mg per day for 21 days followed by seven days rest in a 28 day cycle. 
     
     
         13 . The method of  claim 12 , further comprising administration of rituximab in an amount of 375 mg/m 2  by intravenous infusion weekly. 
     
     
         14 . A method of treating mantle cell lymphoma, which comprises administering to a patient having mantle cell lymphoma from about 5 mg to about 50 mg of 3-(4-amino-oxo-1, 3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a therapeutically effective amount of a second active agent selected from a hematopoietic growth factor, a cytokine, an anti-cancer agent, an antibiotic, a cox-2 inhibitor, a corticosteroid, rituximab, or a combination thereof. 
     
     
         15 . The method of  claim 14 , wherein the second active agent is irtuximab. 
     
     
         16 . The method of  claim 14 , wherein the second active agent is dexamethasone. 
     
     
         17 . The method of  claim 14 , wherein the second active agent is prednisone.